Insider · CIK 0001883821

Haas Jason

Reports to the SEC for 3 companies · JUPITER, FL

sec.gov

Transactions

Companies

Filings

CIK

0001883821

Forms 4 and 5

Insider transactions

44 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+6,138 sh	$51.56	+$316K	11,119
2026-08-12	LGNDLIGAND PHARMACEUTICALS INCS Sale	Director	SSale	−7,138 sh	$292.81	−$2.09M	3,981
2026-08-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,138 sh	—	—	0
2026-06-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	$51.56	+$155K	10,442
2026-06-12	LGNDLIGAND PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+1,000 sh	$51.56	+$51.6K	11,442
2026-06-12	LGNDLIGAND PHARMACEUTICALS INCS Sale	Director	SSale	−3,000 sh	$255.01	−$765K	8,442
2026-06-12	LGNDLIGAND PHARMACEUTICALS INCS Sale	Director	SSale	−3,461 sh	$256.08	−$886K	4,981
2026-06-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	7,138
2026-06-12	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,000 sh	—	—	6,138
2026-06-05	LGNDLIGAND PHARMACEUTICALS INCA Award	Director	AAward	+836 sh	—	—	7,442
2026-06-05	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+2,938 sh	—	—	2,938
2026-05-08	ODTXOdyssey Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+1,000 sh	$20.00	+$20K	62,908
2025-06-06	LGNDLIGAND PHARMACEUTICALS INCA Award	Director	AAward	+1,209 sh	—	—	6,606
2025-06-06	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+5,783 sh	—	—	5,783
2024-11-18	Syros Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−138K sh	$0.21	−$29K	0
2024-10-31	Syros Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+18.9K sh	—	—	143,427
2024-10-31	Syros Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,624 sh	$2.09	−$11.8K	137,803
2024-10-31	Syros Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−18.9K sh	—	—	0
2024-09-12	Syros Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+45.3K sh	$1.68	+$76K	124,552
2024-09-11	Syros Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+19.3K sh	$1.58	+$30.4K	79,208
2024-09-10	Syros Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+35.4K sh	$1.55	+$54.8K	59,915
2024-06-14	LGNDLIGAND PHARMACEUTICALS INCA Award	Director	AAward	+1,252 sh	—	—	5,397
2024-06-14	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+5,444 sh	—	—	5,444
2024-04-01	Syros Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,732 sh	$5.12	−$24.2K	24,552
2024-03-31	Syros Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	15,951
2024-03-31	Syros Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13.3K sh	—	—	29,284
2024-03-31	Syros Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	4,000
2024-03-31	Syros Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13.3K sh	—	—	26,667
2023-11-01	Syros Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−6,301 sh	$2.22	−$14K	13,951
2023-10-31	Syros Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+18.9K sh	—	—	20,252
2023-10-31	Syros Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−18.9K sh	—	—	18,875
2023-06-09	LGNDLIGAND PHARMACEUTICALS INCA Award	Director	AAward	+1,142 sh	—	—	4,145
2023-06-09	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+5,461 sh	—	—	5,461
2023-04-03	Syros Pharmaceuticals, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−623 sh	$2.58	−$1,607.34	1,377
2023-03-31	Syros Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	2,000
2023-03-31	Syros Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	6,000
2023-02-16	Syros Pharmaceuticals, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+40K sh	—	—	40,000
2022-10-06	Syros Pharmaceuticals, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+49.8K sh	—	—	49,750
2022-10-06	Syros Pharmaceuticals, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+37.8K sh	—	—	37,750
2022-06-29	LGNDLIGAND PHARMACEUTICALS INCA Award	Director	AAward	+1,750 sh	—	—	1,750
2022-06-29	LGNDLIGAND PHARMACEUTICALS INC · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+5,907 sh	—	—	5,907
2022-02-15	Syros Pharmaceuticals, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+125K sh	—	—	125,000
2022-02-15	Syros Pharmaceuticals, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+80K sh	—	—	80,000
2021-10-12	Syros Pharmaceuticals, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+750K sh	—	—	750,000

Recent filings

Accepted (ET)
Aug 144
Haas Jason0002001011-26-000114
SEC(opens sec.gov)
Jun 154
Haas Jason0002001011-26-000104
SEC(opens sec.gov)
Jun 94
Haas Jason0002001011-26-000097
SEC(opens sec.gov)
May 114
Haas Jason0001193125-26-217600
SEC(opens sec.gov)
Jun 104
Haas Jason0002001011-25-000040
SEC(opens sec.gov)
Nov 204
Haas Jason0000950170-24-129378
SEC(opens sec.gov)
Nov 44
Haas Jason0000950170-24-120869
SEC(opens sec.gov)
Sep 124
Haas Jason0000950170-24-105995
SEC(opens sec.gov)

Companies

Address

555 HERITAGE DRIVE SUITE 200

JUPITER, FL, 33458